FDA 483 - OMEZA LLC - July 28, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of OMEZA LLC in Sarasota, FL, a drug manufacturer, revealed significant deficiencies across multiple systems. Observations included unsanitary facility conditions with mold, pests, and structural issues, as well as failures in equipment cleaning procedures. The firm also lacked adequate testing for active ingredients in finished products, stability data for OTC drugs, and proper identity testing for incoming raw materials, indicating a broad lack of quality control.
ID · 64d6f9d8-923b-4f82-bb57-152913ace1eb